GU Cancer

A032103

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

---

EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice

---

ALLIANCE A212102 **AT MBMC ONLY** ***Participant Engagement Portal (PEP) is Closed to New Patient Registration as of 9/15/25*** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**

Blinded Reference Set For Multicancer Early Detection Blood Tests

---

S2013: I-CHECKIT ***Only Cohort 2 is open to enrollment***

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

---

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

---

A031702 (Cohort B (adenocarcinoma of the bladder), E (penile cancer), F (sarcomatoid renal cell carcinoma), G (miscellaneous GU tract histologic variants), I (renal medullary carcinoma) and Cohort K (Renal Collecting Duct Carcinoma) are Temporarily Closed to Accrual)

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

---

S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

---

AGCT 1531 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

---